2FJ0 Stock Overview
Pierrel S.p.A. engages in the development, production, registration, and licensing of synthetic drugs and medical devices for the oral health sector worldwide. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 4/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Pierrel S.p.A. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €1.69 |
52 Week High | €4.51 |
52 Week Low | €0.094 |
Beta | 0.47 |
11 Month Change | 2.42% |
3 Month Change | -6.63% |
1 Year Change | -58.32% |
33 Year Change | -55.53% |
5 Year Change | -51.71% |
Change since IPO | -53.38% |
Recent News & Updates
Recent updates
Shareholder Returns
2FJ0 | DE Pharmaceuticals | DE Market | |
---|---|---|---|
7D | 0% | -7.5% | -0.5% |
1Y | -58.3% | -24.1% | 8.3% |
Return vs Industry: 2FJ0 underperformed the German Pharmaceuticals industry which returned -27.5% over the past year.
Return vs Market: 2FJ0 underperformed the German Market which returned 0.1% over the past year.
Price Volatility
2FJ0 volatility | |
---|---|
2FJ0 Average Weekly Movement | 5.0% |
Pharmaceuticals Industry Average Movement | 6.9% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 11.0% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 2FJ0 has not had significant price volatility in the past 3 months.
Volatility Over Time: 2FJ0's weekly volatility has decreased from 12% to 5% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1948 | 105 | Fulvio Citaredo | www.pierrelgroup.com |
Pierrel S.p.A. engages in the development, production, registration, and licensing of synthetic drugs and medical devices for the oral health sector worldwide. It develops and markets dental anesthesia drugs under the Orabloc brand. The company also offers Goccles, a device for screening of the oral cavity.
Pierrel S.p.A. Fundamentals Summary
2FJ0 fundamental statistics | |
---|---|
Market cap | €92.83m |
Earnings (TTM) | €3.11m |
Revenue (TTM) | €26.96m |
29.9x
P/E Ratio3.4x
P/S RatioIs 2FJ0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
2FJ0 income statement (TTM) | |
---|---|
Revenue | €26.96m |
Cost of Revenue | €13.35m |
Gross Profit | €13.61m |
Other Expenses | €10.50m |
Earnings | €3.11m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | 0.057 |
Gross Margin | 50.48% |
Net Profit Margin | 11.53% |
Debt/Equity Ratio | 109.7% |
How did 2FJ0 perform over the long term?
See historical performance and comparison